Pasithea Therapeutics Cor... (KTTA)
NASDAQ: KTTA
· Real-Time Price · USD
0.69
-0.01 (-1.81%)
At close: Aug 15, 2025, 10:09 AM
-1.81% (1D)
| Bid | 0.67 |
| Market Cap | 5.14M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -13.61M |
| EPS (ttm) | -10.6 |
| PE Ratio (ttm) | -0.07 |
| Forward PE | n/a |
| Analyst | n/a |
| Ask | 0.69 |
| Volume | 3,760 |
| Avg. Volume (20D) | 534,670 |
| Open | 0.71 |
| Previous Close | 0.70 |
| Day's Range | 0.68 - 0.71 |
| 52-Week Range | 0.65 - 7.50 |
| Beta | 0.26 |
About KTTA
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol KTTA
Website n/a
3 months ago
+11.09%
Pasithea Therapeutics shares are trading higher af...
Unlock content with
Pro Subscription
3 months ago
+11.07%
Pasithea Therapeutics shares are trading higher after the company announced initiation of its Phase 1/1b open label study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of PAS-004, in adult participants with neurofibromatosis type 1 with symptomatic and inoperable, incompletely resected, or recurrent plexiform neurofibromas.
